专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010008135A1 ORAL SOFT CAPSULE OF ACECLOFENAC HAVING IMPROVED STABILITY 审中-公开
标题翻译：具有改善稳定性的ACECLOFENAC口服软胶囊
公开(公告)号：WO2010008135A1
公开(公告)日：2010-01-21
申请号：PCT/KR2009/002249
申请日：2009-04-29
申请人： KOREA UNITED PHARM, INC , CHOI, Youn-Woong , CHO, Sang-Min , HA, Dae-Chul , AN, Seung-Ho
发明人： CHOI, Youn-Woong , CHO, Sang-Min , HA, Dae-Chul , AN, Seung-Ho
IPC分类号： A61K9/48 , A61K31/353 , A61K9/107 , A61K47/00 , A61K9/52 , A61K9/64 , A61K9/66
CPC分类号： A61K9/4858 , A61K31/216
摘要： The present invention relates to an aceclofenac-containing soft capsule formulation having improved stability and the preparation thereof, and more particularly to a method of preparing a soft capsule by dissolving or dispersing aceclofenac, which is unstable in an aqueous solution, in oil or a mixture of oils. The aceclofenac-containing soft capsule contains an aceclofenac-containing liquid composition prepared by mixing and solubilizing aceclofenac, oil and a suspending agent. The soft capsule can maintain stability for 3 years or more and has improved active ingredient dissolution compared to existing soft capsules, thus increasing the bioavailability of the active ingredient.
摘要翻译：本发明涉及具有改进的稳定性及其制备的含有醋氯芬酸的软胶囊制剂，更具体地涉及通过将在水溶液中不稳定的醋氯芬酸溶解或分散在油或混合物中来制备软胶囊的方法的油。含有醋氯芬酸的软胶囊含有通过混合和增溶醋氯芬酸，油和悬浮剂制备的含有醋氯芬酸的液体组合物。软胶囊可以保持3年以上的稳定性，并且与现有的软胶囊相比具有改善的活性成分溶解度，从而提高活性成分的生物利用度。

2. 发明申请

WO2008018778A1 NEW HETEROCYCLIC COMPOUNDS CONTAINING NITROGEN ATOMS OR PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, PROCESS FOR THE PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME FOR TREATMENT OF CANCER 审中-公开
标题翻译：含有氮原子或其药学上可接受的盐的新的杂环化合物，其制备方法和包含其的治疗癌症的药物组合物
公开(公告)号：WO2008018778A1
公开(公告)日：2008-02-14
申请号：PCT/KR2007/003861
申请日：2007-08-10
申请人： KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY , SEOUL PHARMA. CO., LTD. , HAN, Gyoon Hee , CHOI, Eun Hyun , YANG, Jee Sun , HONG, Sung Hee , KIM, Myung Sook , WON, Mi Sun , CHUNG, Kyung Sook , KIM, Dong Myung , YOO, Hyang Sook , KIM, Hwan Mook , PARK, Song Kyu , LEE, Ki Ho , LEE, Chang Woo , CHOI, Youn Woong , JEONG, Yong Mi , MIN, Byung Gu
发明人： HAN, Gyoon Hee , CHOI, Eun Hyun , YANG, Jee Sun , HONG, Sung Hee , KIM, Myung Sook , WON, Mi Sun , CHUNG, Kyung Sook , KIM, Dong Myung , YOO, Hyang Sook , KIM, Hwan Mook , PARK, Song Kyu , LEE, Ki Ho , LEE, Chang Woo , CHOI, Youn Woong , JEONG, Yong Mi , MIN, Byung Gu
IPC分类号： C07D295/185 , C07D241/04 , C07D243/08 , A61P35/00
CPC分类号： C07D295/185 , C07D243/08 , C07D295/26
摘要： The present invention relates to new heterocyclic compounds containing nitrogen atoms or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and a phar¬ maceutical composition comprising the same for treatment of cancer. The compounds according to the present invention induce DNA damage due to reactive oxygen species to activate c-abl and p53, induce RhoB to generate apoptosis, and induce cell death by down-regulating Bcl2 involved in cell survival, which is generated by dysregulated signals via the mitochondria pathway, thereby inhibiting tumor cell growth and inducing apoptosis. Accordingly, the composition according to the present invention can be used to treat cancer.
摘要翻译：本发明涉及含有氮原子的新型杂环化合物或其药学上可接受的盐，其制备方法和包含其的用于治疗癌症的药物组合物。根据本发明的化合物诱导由于活性氧物质引起的DNA损伤以激活c-abl和p53，诱导RhoB产生细胞凋亡，并通过下调参与细胞存活的Bcl2诱导细胞死亡，其由失调信号通过线粒体途径，从而抑制肿瘤细胞生长并诱导细胞凋亡。因此，本发明的组合物可以用于治疗癌症。

3. 发明申请

WO2011152652A2 ACECLOFENAC SLOW-RELEASE PREPARATION PROVIDING AN OPTIMUM PHARMACOLOGICAL CLINICAL EFFECT WHEN ADMINISTERED ONCE A DAY 审中-公开
标题翻译： ACECLOFENAC缓释制剂在一天内施用时提供最佳的药理学临床效果
公开(公告)号：WO2011152652A2
公开(公告)日：2011-12-08
申请号：PCT/KR2011003989
申请日：2011-06-01
申请人： KOREA UNITED PHARM INC , LEE BEOM JIN , JUNG WON-TAE , CHOI YOUN WOONG , NAM KYU YEOL , CHO SANG-MIN , JANG JAE SANG , CHOI MINJI
发明人： LEE BEOM JIN , JUNG WON-TAE , CHOI YOUN WOONG , NAM KYU YEOL , CHO SANG-MIN , JANG JAE SANG , CHOI MINJI
IPC分类号： A61K9/22 , A61K9/20 , A61K31/216 , A61K47/38
CPC分类号： A61K9/209 , A61K31/216
摘要： The present invention relates to a controlled-release preparation administered orally once a day that exhibits an optimum pharmacological clinical effect, featuring two-layer tablets, dual tablets and multilayered tablets having a fast-release layer comprising aceclofenac, a water-soluble additive, a non-soluble additive, a solubilizer, a disintegrator and a filler, and a slow-release layer comprising aceclofenac, a slow-release base, a disintegrator, a binder, a filler, a fluidizer, a solubilizer and a lubricant.
摘要翻译：本发明涉及具有最佳药理临床效果的一天一次口服的控释制剂，其特征在于具有快速释放层的双层片剂，双片剂和多层片剂，其包含醋氯芬酸，水溶性添加剂，不溶性添加剂，增溶剂，崩解剂和填料，以及包含醋氯芬酸，缓释碱，崩解剂，粘合剂，填料，流化剂，增溶剂和润滑剂的缓释层。

4. 发明申请

WO2009031749A1 A NOVEL CONTROLLED RELEASE-NIACIN FORMULATION 审中-公开
标题翻译：一种新型的控释释放制剂
公开(公告)号：WO2009031749A1
公开(公告)日：2009-03-12
申请号：PCT/KR2008/002737
申请日：2008-05-16
申请人： SEOUL PHARMA. CO., LTD. , CHOI, Youn Woong , MIN, Byung Gu , CHO, Sang Min
发明人： CHOI, Youn Woong , MIN, Byung Gu , CHO, Sang Min
IPC分类号： A61K47/48
CPC分类号： A61K31/455 , A61K9/2027 , A61K9/2054
摘要： The present invention relatestoa cont rolled-re lease niacin formulation. In particular, the present invention relates to a controlled-release niacin formulation, comprising niacin; hydroxypropyl methylcellulose; and a carboxyvinyl polymer, in which the carboxyvinyl polymer and hydroxypropyl methylcellulose are contained in a predetermined weight ratio, and to a preparation method thereof. The controlled-release niacin formulation according to the present invention maintains its matrix shape until completion of release, and also release pattern without fluctuation for a desired time period, unlike other formulations. Inparticular, since niacin formulations are used for long-term treatment of hyperlipidemia, the controlled-release niacin formulation of the present invention, capable of maintaining effective blood concentration and high stability for a long period of time, is very useful.
摘要翻译：本发明涉及一种续卷烟酸制剂。特别地，本发明涉及一种控释烟酸制剂，其包含烟酸; 羟丙基甲基纤维素; 羧基乙烯基聚合物及其制备方法，其中羧乙烯基聚合物和羟丙基甲基纤维素以预定的重量比包含。根据本发明的控释烟酸制剂保持其基质形状直到释放完成，并且与其他制剂不同，也可以在不期望的时间段内释放出不变形的图案。特别地，由于烟酸制剂用于高脂血症的长期治疗，因此能够长时间保持有效血液浓度和高稳定性的本发明的控制释放烟酸制剂是非常有用的。

5. 发明申请

WO2004006904A1 ORAL CONTROLLED-RELEASE DOSAGE FORMS CONTAINING ACETAMINOPHEN 审中-公开
标题翻译：口服控制释放含有乙酰氨基酚的剂型
公开(公告)号：WO2004006904A1
公开(公告)日：2004-01-22
申请号：PCT/KR2003/001036
申请日：2003-05-27
申请人： SEOUL PHARM. CO., LTD. , LEE, Beom-Jin , CAO, Qing-Ri , CHOI, Youn-Woong
发明人： LEE, Beom-Jin , CAO, Qing-Ri , CHOI, Youn-Woong
IPC分类号： A61K31/165
CPC分类号： A61K9/2013 , A61K9/2054 , A61K9/2059 , A61K31/165
摘要： The present invention relates to oral dosage forms containing acetaminophen. More particularly, the present invention relates to oral dosage forms containing acetaminophen as a model drug, polymer base, disintegrants and lubricant, where the water-soluble additives further are contained in the said preparations. The dosage forms of the present invention are formulated to various formulations such as tablet, compressed pellet, granule and capsule. Upon exposure to the various dissolution media, the oral dosage forms of the present invention absorb water and form a gel structure, showing rapidly release of 50 % drug within a few minutes like a commercial two-layered tablet followed by the extended release thereafter. The release rate of drug is mainly governed by the swelling and erosion rate of the polymer base together with additives incorporated in matrix tablet. Unlike the two-layered commercial tablet, the new heterodisperse and single-layered HPMC matrix tablet could be easily prepared by using conventional tablet machine. The dosage forms also provide an economical and unique preparation method.
摘要翻译：本发明涉及含有对乙酰氨基酚的口服剂型。更具体地，本发明涉及含有对乙酰氨基酚作为模型药物，聚合物基质，崩解剂和润滑剂的口服剂型，其中所述制剂中还含有水溶性添加剂。将本发明的剂型配制成各种制剂，例如片剂，压片剂，颗粒剂和胶囊剂。在暴露于各种溶解介质时，本发明的口服剂型吸收水并形成凝胶结构，在几分钟内如商业双层片剂快速释放50％的药物，随后延长释放。药物的释放速度主要由聚合物基质的膨胀和侵蚀速率以及掺入基质片剂中的添加剂所决定。与两层商业片剂不同，新型异分散和单层HPMC基质片可以通过使用传统的压片机容易地制备。剂型还提供了经济且独特的制备方法。

6. 发明申请

WO2012148181A3 COMPOSITION FOR THE CONTROLLED-RELEASE OF DRUGS 审中-公开
标题翻译：用于控制释放药物的组合物
公开(公告)号：WO2012148181A3
公开(公告)日：2012-12-20
申请号：PCT/KR2012003223
申请日：2012-04-26
申请人： KOREA UNITED PHARM INC , CHOI YOUN-WOONG , CHO SANG MIN , MIN BYUNG GU , PARK JIN HA , KIM BO KYUNG
发明人： CHOI YOUN-WOONG , CHO SANG MIN , MIN BYUNG GU , PARK JIN HA , KIM BO KYUNG
IPC分类号： A61K9/22 , A61K9/20 , A61K47/30 , A61K47/38
CPC分类号： A61K9/2054 , A61K9/2013 , A61K9/2027
摘要： The present invention relates to a composition for the controlled-release of drugs. More particularly, the composition for the controlled-release of drugs according to the present invention expands the capacity for the controlled-release of a matrix-type polymer for controlled-release via a carbomer in which said polymer for controlled-release forms a basic frame and in which sol-gel transition occurs in accordance with a pH level. The composition of the present invention is characterized in that it comprises: a solubilizing agent for the event the drug to be released is highly insoluble, and a disintegrating agent for sufficient initial release. The composition for the controlled-release of drugs according to the present invention uses a carbomer which maintains the controlled-release of conventional matrix structures having polymers for controlled-release and which has sol-gel transition properties, thus preventing a sudden release of a drug caused by a collapse of the matrix structure during a late stage of elution. In addition, the composition of the present invention uses a solubilizing agent to solve the problem of a highly insoluble drug failing to dissolve even after being released, and also uses a disintegrating agent to improve the speed of the initial release, which is the limiting factor in controlled-release preparations.
摘要翻译：本发明涉及用于药物控制释放的组合物。更具体地说，根据本发明的用于药物控制释放的组合物通过卡波姆扩大了用于控制释放的基质型聚合物的释放能力，其中所述控释聚合物形成基本框架并且其中根据pH水平发生溶胶 - 凝胶转变。本发明的组合物的特征在于，它包括：用于释放药物高度不溶性的增溶剂，以及用于充分初始释放的崩解剂。根据本发明的用于药物控制的组合物使用卡波姆，其维持具有用于控制释放的聚合物的常规基质结构的控制释放，并且具有溶胶 - 凝胶转变特性，从而防止药物的突然释放由洗脱后期的基体结构的崩溃引起的。此外，本发明的组合物使用增溶剂来解决即使在剥离后不能溶解的高度不溶性药物的问题，并且还使用崩解剂来提高初始释放的速度，这是限制因素在控释制剂中。

7. 发明申请

WO2010104253A1 MULTIFUNCTIONAL CONTRAST AGENT USING BIOCOMPATIBLE POLYMER AND PREPARATION METHOD 审中-公开
标题翻译：多功能对比剂使用生物聚合物和制备方法
公开(公告)号：WO2010104253A1
公开(公告)日：2010-09-16
申请号：PCT/KR2009/005533
申请日：2009-09-28
申请人： KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY , KOREA UNITED PHARM. INC. , CHO, Sun Hang , SHIN, Byung Cheol , YUK, Soon Hong , SEONG, Ha Soo , KIM, Byung Jin , KIM, Hyo Jeong , CHOI, Youn Woong , MIN, Byung Gu , HA, Dae Chul
发明人： CHO, Sun Hang , SHIN, Byung Cheol , YUK, Soon Hong , SEONG, Ha Soo , KIM, Byung Jin , KIM, Hyo Jeong , CHOI, Youn Woong , MIN, Byung Gu , HA, Dae Chul
IPC分类号： C08G73/10 , C08G73/00 , A61K49/06 , A61P35/00
CPC分类号： A61K49/0032 , A61K49/0043 , A61K49/0054 , A61K49/12 , Y10T428/2982
摘要： The present invention relates to a biocompatible contrast agent and a method of its preparation. More particularly, the present invention relates to a multifunctional contrast agent manufactured by prepairing a novel polysuccinimide-based polymer by introducing an alkanolamine group to the main group of the pioysuccinimide in addition to a biocompatible hydrophilic group, which improves bioavailability, and a hydrophobic group, which enables to maintain the form of stable nanoparticles during the formation of nano particles for a long period of time and to encapsulate a hydrophobic anticancer agent.
摘要翻译：本发明涉及一种生物相容性造影剂及其制备方法。更具体地说，本发明涉及一种多功能造影剂，其是通过将生物相容性亲水基除了提高生物利用度之外，通过将链烷醇胺基引入到聚对苯二甲酰亚胺的主要基团中而制备新的聚琥珀酰亚胺类聚合物，这使得能够在长时间形成纳米颗粒期间保持稳定的纳米颗粒的形式并且包封疏水性抗癌剂。

8. 发明申请

WO2010090371A1 ACECLOFENAC-CONTAINING CONTROLLED-RELEASE ORAL DRUG PREPARATIONS AND THEIR MANUFACTURING PROCESS 审中-公开
标题翻译：含有控释的口服药物制剂及其制造过程
公开(公告)号：WO2010090371A1
公开(公告)日：2010-08-12
申请号：PCT/KR2009/002251
申请日：2009-04-29
申请人： KOREA UNITED PHARM, INC , LEE, Beom-Jin , CHOI, Youn-Woong , MIN, Byung-Gu , AN, Seung-Ho
发明人： LEE, Beom-Jin , CHOI, Youn-Woong , MIN, Byung-Gu , AN, Seung-Ho
IPC分类号： A61K9/24 , A61K9/22 , A61K47/30 , A61K9/54
CPC分类号： A61K9/209
摘要： Disclosed herein are single-layer and double-layer tablets, which release aceclofenac in a controlledmanner so as to achieve ideal drug release close to a straight line. Also, the tablets promote drug absorption in the stomach by controlling pH, contain aceclofenac with improved stability and haveboth immediate-release properties and sustained-release properties. Specifically, provided is an aceclofenac sustained-release tablet which is composed of an immediate-release layer containing aceclofenac, a water-soluble additive, a pH-controlling agent, a disintegrant, a filler and a lubricant and of a sustained-release layer containing aceclofenac, a release-controlling polymer, an oil-soluble surfactant, a filler and a lubricant, wherein the pH-controlling agent is sodium hydrogen carbonate, and the release-controlling polymer is a mixture of hydroxypropylmethylcellulose and carbomer.
摘要翻译：本文公开了单层和双层片剂，其在受控制剂中释放乙氯芬酸以便实现靠近直线的理想药物释放。此外，片剂通过控制pH促进胃中的药物吸收，含有改善的稳定性的乙酰苯胺酸，并且具有即时释放性质和持续释放性质。具体地说，本发明提供了一种醋氯芬酸缓释片剂，其由含有醋氯芬酸的速释层，水溶性添加剂，pH控制剂，崩解剂，填充剂和润滑剂以及缓释层醋氯芬酸，释放控制性聚合物，油溶性表面活性剂，填充剂和润滑剂，其中所述pH控制剂为碳酸氢钠，所述释放控制聚合物为羟丙基甲基纤维素和卡波姆的混合物。

9. 发明申请

WO2009148245A4 NOVEL NIACIN AND HMG-COA REDUCTASE INHIBITOR COMBINATION FORMULATION 审中-公开
标题翻译：新型氨基酸和HMG-COA还原抑制剂组合制剂
公开(公告)号：WO2009148245A4
公开(公告)日：2010-04-22
申请号：PCT/KR2009002923
申请日：2009-06-02
申请人： SEOUL PHARMA CO LTD , CHOI YOUN-WOONG , MIN BYUNG-GU , CHO SANG-MIN , KIM JONG-IL , KIM DAE-WOOK , JEONG YONG-MI , JANG JAE-SANG , RYOO BYUNG-HWAN
发明人： CHOI YOUN-WOONG , MIN BYUNG-GU , CHO SANG-MIN , KIM JONG-IL , KIM DAE-WOOK , JEONG YONG-MI , JANG JAE-SANG , RYOO BYUNG-HWAN
IPC分类号： A61K9/22 , A61K9/20 , A61K9/26 , A61K47/38
CPC分类号： A61K9/2054
摘要： The present invention relates to a controlled release formulation containing niacin. More specifically, the present invention relates to a controlled release-niacin formulation and a preparation method thereof, wherein the controlled release-niacin formulation comprises niacin, hydroxypropyl methylcellulose, carboxyvinyl polymers, additives, disintegrants, and lubricants, wherein the carboxyvinyl polymer and hydroxypropyl methylcellulose are included so that the weight ratio of the carboxyvinyl polymer: HPMC is 1:1 - 1:100. In addition, the present invention provides a combination formulation further containing an HMG-CoA reductase inhibitor in the controlled release-niacin formulation and a preparation method thereof.
摘要翻译：本发明涉及含有烟酸的控释制剂。更具体地说，本发明涉及控释烟酸制剂及其制备方法，其中控制释放 - 烟酸配制剂包含烟酸，羟丙基甲基纤维素，羧基乙烯基聚合物，添加剂，崩解剂和润滑剂，其中羧基乙烯基聚合物和羟丙基甲基纤维素以使得羧基乙烯基聚合物：HPMC的重量比为1:1-1:100。此外，本发明提供了在控释硝酸配方中进一步含有HMG-CoA还原酶抑制剂的组合制剂及其制备方法。

10. 发明申请

WO2009148245A2 NOVEL NIACIN AND HMG-COA REDUCTASE INHIBITOR COMBINATION FORMULATION 审中-公开
标题翻译：新型氨基酸和HMG-COA还原抑制剂组合制剂
公开(公告)号：WO2009148245A2
公开(公告)日：2009-12-10
申请号：PCT/KR2009002923
申请日：2009-06-02
申请人： SEOUL PHARMA CO LTD , CHOI YOUN-WOONG , MIN BYUNG-GU , CHO SANG-MIN , KIM JONG-IL , KIM DAE-WOOK , JEONG YONG-MI , JANG JAE-SANG , RYOO BYUNG-HWAN
发明人： CHOI YOUN-WOONG , MIN BYUNG-GU , CHO SANG-MIN , KIM JONG-IL , KIM DAE-WOOK , JEONG YONG-MI , JANG JAE-SANG , RYOO BYUNG-HWAN
IPC分类号： A61K9/22
CPC分类号： A61K9/2054
摘要： The present invention relates to a controlled release formulation containing niacin. More specifically, the present invention relates to a controlled release-niacin formulation and a preparation method thereof, wherein the controlled release-niacin formulation comprises niacin, hydroxypropyl methylcellulose, carboxyvinyl polymers, additives, disintegrants, and lubricants, wherein the carboxyvinyl polymer and hydroxypropyl methylcellulose are included so that the weight ratio of the carboxyvinyl polymer: HPMC is 1:1 - 1:100. In addition, the present invention provides a combination formulation further containing an HMG-CoA reductase inhibitor in the controlled release-niacin formulation and a preparation method thereof.
摘要翻译：本发明涉及含有烟酸的控释制剂。更具体地说，本发明涉及控释烟酸制剂及其制备方法，其中控制释放 - 烟酸配制剂包含烟酸，羟丙基甲基纤维素，羧基乙烯基聚合物，添加剂，崩解剂和润滑剂，其中羧基乙烯基聚合物和羟丙基甲基纤维素以使得羧基乙烯基聚合物：HPMC的重量比为1:1-1:100。此外，本发明提供了在控释硝酸配方中进一步含有HMG-CoA还原酶抑制剂的组合制剂及其制备方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式